Autoimmune hepatitis (AIH) is a chronic - or long lasting - disease in which the body's immune system attacks the normal components, or cells, of the liver and causes inflammation and liver damage.
Autoimmune Hepatitis Research Studies
Investigator
Open Research Studies for Autoimmune Hepatitis
GRACE: Autoimmune Hepatitis Database
Enrolling: Yes
Principle Investigator: Craig Lammert, MD
Duration: 1 visit
Patient Population: Autoimmune Hepatitis/Pre- and Post- Transplant/Overlap
Interested in this study? Please contact the coordinator below:
Kelsey Green
greenke@iu.edu
(317) 278-9292
A Randomized, Double-blind, Placebo-controlled, Phase 2a Study to Evaluate the Safety and Efficacy of Zetomipzomib (KZR-616) in Patients with Autoimmune Hepatitis
Enrolling: Yes
Principle Investigator: Craig Lammert, MD
Duration: 4 week screening period, 24 week treatment period, 4 week off-treatment safety follow-up period
Patient Population: AIH who have failed standard-of-care treatment, had an incomplete biochemical response to ≥3 months of standard-of-care treatment, or had a disease flare after standard-of-care treatment.
Drug(s): Zetomipzomib
Interested in this study? Please contact the coordinator below:
Kelsey Green
greenke@iu.edu
(317) 278-9292
Rituximab
Enrolling: Yes
Principle Investigator: Craig Lammert, MD
Duration: 12 months
Patient Population: Aged 18 or greater with AIH.
Drug(s): Rituximab
Interested in this study? Please contact the coordinator below:
Regina Weber
reginaw@iu.edu
(317) 278-3584